


**Daclatasvir**




- Six MPP licensees currently developing the two products, of which:
  - Four have filed with WHO-PQ
  - One plans to file in 2019 and another in 2020
- **Cipla, Hetero and Mylan** have received ERP approvals
- Currently approved in 21 countries and filed in another 29 countries

Approved (21)	
Benin	Liberia
Cambodia	Malawi
Chad	Mongolia
Congo	Myanmar
DR Congo	Nicaragua
Dominican Republic	Pakistan
Ethiopia	Philippines
Gabon	Tanzania
Guyana	Turkmenistan
India	Uzbekistan
Indonesia	

Filed (29)		
Azerbaijan	Guatemala	Senegal
Bolivia	Haiti	Sri Lanka
Botswana	Honduras	Sudan
Burkina Faso	Kenya	Suriname
Burundi	Lao PDR	Togo
Cameroon	Namibia	Uganda
Costa Rica	Malaysia	Vietnam
Côte d'Ivoire	Nigeria	Zambia
Georgia	Paraguay	Zimbabwe
Ghana	Rwanda	

Generic DAC has been filed in 50 countries, of which approval is received from 21.



- Currently two MPP licensees are developing DAC/SOF combination, of which:
  - One licensee has filed with WHO-PQ in Sep-18
  - Another licensee plans to file in 2020
- Currently approved in three countries and filed in another 16 countries

## Approved (3)

India

Libya

Nicaragua

## Filed (16)

Côte d'Ivoire

Namibia

Dominican Republic

Nigeria

Ethiopia

Paraguay

Ghana

Suriname

Guyana

Tanzania

Kenya

Vietnam

Malawi

Zambia

Myanmar

Zimbabwe

DAC/SOF has been filed in 19 countries, of which approval is received from three.